HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.

AbstractBACKGROUND:
Omalizumab has demonstrated clinical benefits in children with moderate to severe allergic asthma. However, no studies have been performed in Japanese asthmatic children. The aim of this study was to evaluate the efficacy including free IgE suppression and safety of omalizumab in Japanese children with severe allergic asthma. The primary objective was to examine whether omalizumab decreases serum free IgE levels to less than 25 ng/ml (target level of suppression).
METHODS:
Thirty-eight Japanese children (6-15 years) with uncontrolled severe allergic asthma despite inhaled corticosteroids (>200 μg/day fluticasone propionate or equivalent) and two or more controller therapies received add-on treatment with omalizumab in a 24-week, multicenter, uncontrolled, open-label study.
RESULTS:
The geometric mean serum free IgE level at 24 weeks was 15.6 ng/mL. Compared with baseline, total asthma symptom scores, daily activity scores and nocturnal sleep scores at 24 weeks were significantly improved. The rates of asthma exacerbation and hospitalization due to asthma were reduced by 69.2% and 78.2%, respectively (p < 0.001), versus baseline. Quality-of-life scores were also significantly improved (p < 0.001). In addition, 11 (28.9%) patients reduced the dose of any asthma controller medications. Thirty-six (94.7%) patients experienced at least one adverse event during the treatment period. All adverse events were mild or moderate in severity and no new safety concerns were detected. No patients discontinued the study.
CONCLUSIONS:
In Japanese children with severe allergic asthma, omalizumab decreased free IgE levels to less than 25 ng/mL. Omalizumab improved asthma control and was well-tolerated, as well.
AuthorsHiroshi Odajima, Motohiro Ebisawa, Toshikazu Nagakura, Takao Fujisawa, Akira Akasawa, Komei Ito, Satoru Doi, Koichi Yamaguchi, Toshio Katsunuma, Kazuyuki Kurihara, Naomi Kondo, Kazuko Sugai, Mitsuhiko Nambu, Akira Hoshioka, Shigemi Yoshihara, Norio Sato, Noriko Seko, Sankei Nishima
JournalAllergology international : official journal of the Japanese Society of Allergology (Allergol Int) Vol. 64 Issue 4 Pg. 364-70 (Oct 2015) ISSN: 1440-1592 [Electronic] England
PMID26433533 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.
Chemical References
  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Omalizumab
  • Immunoglobulin E
Topics
  • Adolescent
  • Anti-Asthmatic Agents (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Anti-Idiotypic (administration & dosage, adverse effects, therapeutic use)
  • Asthma (diagnosis, drug therapy, immunology)
  • Child
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoglobulin E (blood, immunology)
  • Japan
  • Male
  • Omalizumab (administration & dosage, adverse effects, therapeutic use)
  • Quality of Life
  • Respiratory Function Tests
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: